- •BRCA1 dysfunction alters the immunophenotype of ovarian cancer cells.
- •BRCA1− tumors are susceptible to immunomodulation by PLD.
- •BRCA1 ovarian cancer patients are candidates for PLD combined with immunotherapy.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.Cancer. 2005; 104: 2807-2816
- Improved survival in women with BRCA-associated ovarian carcinoma.Cancer. 2003; 97: 2187-2195
- A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer.Gynecol Oncol. 2011; 123: 486-491
- Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18.J Transl Med. 2009; 7: 104
- Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death.J Exp Med. 2005; 202: 1691-1701
- Calreticulin exposure dictates the immunogenicity of cancer cell death.Nat Med. 2007; 13: 54-61
- Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2.Clin Cancer Res. 1999; 5: 687-693
- Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer.Cancer. 2009; 115: 2891-2902
- Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.N Engl J Med. 2003; 348: 203-213
- Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.Mod Pathol. 2009; 22: 393-402
- Induction of ovarian cancer by defined multiple genetic changes in a mouse model system.Cancer Cell. 2002; 1: 53-62
- A mouse model for the molecular characterization of brca1-associated ovarian carcinoma.Cancer Res. 2006; 66: 8949-8953
- A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance.Proc Natl Acad Sci U S A. 2005; 102: 6936-6941
- Cytotoxic T cells.J Invest Dermatol. 2006; 126: 32-41
☆Financial Support: Kaleidoscope of Hope Young Investigator Grant.